FBIO · Fortress Biotech, Inc. · Financials
Market Cap
$92.31M
Shares
36.78M
Income-statement, balance-sheet and cash-flow figures from SEC filings, plus a debt profile anchored in the latest 10-K and updated by each 10-Q and debt exhibit.
Revenue
$63.26M
+9.7%
FY2025
Net Income
$6.82M
+114.8%
FY2025
Gross Margin
66.92%
+3.1pp
FY2025
Operating Margin
-111%
+80.4pp
FY2025
Diluted EPS
-$0.07
+97.4%
FY2025
Operating Cash Flow
-$65.78M
+18%
FY2025
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 | FY2012 | FY2011 | FY2010 | FY2009 | FY2008 | FY2007 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| $68.47M | $63.26M | $57.68M | $84.51M | $75.74M | $68.79M | $45.6M | $36.63M | $26.88M | $17.25M | $16.48M | $863K | $0 | $0 | — | — | — | — | — | — | |
| $4.41M | — | — | — | — | — | — | $11.85K | $10.34K | $7687 | — | — | — | — | — | — | — | — | — | — | |
| $23.56M | $20.92M | $20.88M | $22.89M | $30.78M | $32.08M | $14.59M | $10.53M | $6.13M | $3.66M | $790K | $0 | — | — | — | — | — | — | — | — | |
| $44.91M | $42.34M | $36.8M | $61.62M | $44.97M | $36.71M | $31.01M | $26.1M | $20.76M | $13.59M | $15.69M | $863K | — | — | — | — | — | — | — | — | |
| — | 66.92% | 63.8% | 72.91% | 59.37% | 53.36% | 67.99% | 71.25% | 77.22% | 78.79% | 95.21% | 100% | — | — | — | — | — | — | — | — | |
| $1.18M | $11.9M | $56.63M | $106.07M | $134.88M | $128.87M | $64.11M | $81.33M | $87.38M | $48.32M | $35.13M | $29.81M | $10.24M | $25.68M | $17.47M | $8.58M | $8.34M | $2.27M | — | — | |
| $25.51M | — | — | — | — | — | $17.38M | $17.12M | $11.64M | $10.41M | $5.77M | $2.85M | — | — | — | — | — | — | — | — | |
| $54.04M | — | — | — | — | — | $43.78M | $38.47M | $41.73M | $50.9M | $28.23M | $18.73M | $10.41M | $10.1M | $8.67M | $5.76M | $900K | $343K | — | — | |
| $68.68M | $96.4M | $87.73M | $90.98M | $113.66M | $86.84M | $61.17M | $55.59M | $53.37M | — | — | — | — | — | — | — | — | — | — | — | |
| $4.22M | $4.26M | $3.42M | $3.77M | $4.28M | — | $1.42M | $1.17M | — | $1.65M | $0 | $0 | — | — | — | — | — | — | — | — | |
| — | — | — | — | — | — | — | — | — | $1.17M | $944K | $26K | $23K | $17K | — | — | — | — | — | — | |
| $148.22M | — | — | — | — | — | — | — | $146.88M | $107.04M | $82.19M | $51.39M | $20.65M | $35.78M | — | — | — | — | — | — | |
| $97.64M | $133.48M | $168.05M | $226.86M | $279.31M | $257.33M | $139.87M | $147.45M | $146.88M | — | — | — | — | — | — | — | — | — | — | — | |
| -$29.18M | -$70.22M | -$110.38M | -$142.34M | -$203.56M | -$188.54M | -$94.27M | -$110.82M | -$120M | -$89.8M | -$65.71M | -$50.53M | -$20.65M | -$35.78M | -$27.18M | -$35.04M | -$9.24M | -$2.61M | — | — | |
| — | -111% | -191.38% | -168.43% | -268.76% | -274.08% | -206.74% | -302.54% | -446.38% | -520.71% | -398.73% | -5855.27% | — | — | — | — | — | — | — | — | |
| — | — | — | — | — | — | — | — | — | -$88.63M | -$64.77M | -$50.51M | -$20.63M | -$35.76M | — | — | — | — | — | — | |
| $7.02M | — | — | — | — | — | — | — | — | $5.86M | $3.69M | $1.48M | $1.34M | $1.92M | $670K | $74K | $1.54M | $1.05M | — | — | |
| $3.52M | $2.49M | $2.68M | $3M | $1.4M | $649K | $1.52M | $2.56M | $1.1M | $819K | $298K | $245K | $662K | $545K | $236K | $165K | $61K | — | — | — | |
| $175.2M | $36.69M | -$10.16M | -$11.29M | -$9.9M | $24.19M | -$8.58M | $9.16M | -$10.8M | -$7.72M | -$5.58M | -$3.35M | $266K | -$1.38M | — | — | — | — | — | — | |
| — | — | — | — | — | — | — | — | $2.33M | — | — | — | — | — | — | — | — | — | — | — | |
| $146.03M | -$33.54M | -$120.54M | -$153.63M | -$213.46M | -$164.35M | -$102.85M | -$101.66M | -$130.8M | -$97.51M | -$71.29M | -$53.88M | — | — | — | — | — | — | — | — | |
| $4.83M | -$620K | $312K | $521K | $449K | $473K | $500K | $0 | $0 | $1.51M | $0 | $0 | — | — | — | — | — | — | — | — | |
| $111.82M | $6.82M | -$46M | -$60.64M | -$86.58M | -$64.7M | -$46.53M | -$39.96M | -$84.15M | -$66.88M | -$55.1M | -$48.43M | -$20.39M | -$37.16M | -$27.61M | -$36.36M | -$9.98M | -$3.67M | -$3.8M | -$2.64M | |
| — | 10.77% | -79.75% | -71.75% | -114.3% | -94.06% | -102.03% | -109.09% | -313.02% | -387.8% | -334.31% | -5611.59% | — | — | — | — | — | — | — | — | |
| $29.38M | -$39.73M | -$74.86M | -$93.52M | -$127.34M | -$100.12M | -$56.46M | -$61.7M | -$57.79M | -$32.96M | -$16.2M | -$5.46M | $0 | $0 | — | — | — | — | — | — | |
| $103.37M | -$1.88M | -$55.89M | -$68.67M | -$94.61M | — | — | — | — | — | — | — | — | -$37.16M | -$27.61M | -$42.22M | -$9.98M | -$3.67M | — | — | |
| USD/shares | $3.27 | -$0.07 | -$2.69 | -$8.47 | -$15.97 | -$11.85 | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| USD/shares | $2.70 | -$0.07 | -$2.69 | -$8.47 | -$15.97 | -$11.85 | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| shares | — | 27.9M | 20.78M | 8.11M | 5.92M | 5.45M | 4.8M | 3.65M | 2.9M | 2.78M | 2.66M | 2.61M | 2.42M | 2.03M | 1.44M | 510.87K | 296.92K | — | — | — |
| shares | — | 27.9M | 20.78M | 8.11M | 5.92M | 5.45M | 4.8M | 3.65M | 2.9M | 2.78M | 2.66M | 2.61M | 2.42M | 2.03M | 1.44M | 510.87K | 296.92K | — | — | — |
Italic rows are computed from reported lines — open a row's info icon for its formula. Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative.
Capital Returned to Shareholders
Cash spent on share repurchases and dividends per fiscal year, as reported on the cash-flow statement. Across FY2019–FY2025: $70K in buybacks, $3.83M in dividends.
Debt Profile
Annual debt figures are established from 10-K filings and updated by subsequent 10-Q and 8-K disclosures. Instrument balances are not summed into a company total unless the filing itself reports that total.
Debt data is being processed. Please check back later.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.
Valuation
EV/Revenue
-1.01×
Peer median 5.08×
EV/EBIT
—
Peer median 11.21×
P/E (TTM)
—
Peer median 8.07×
Peer medians compare against the 305 similar-size Biotechnology companies (of 534 listed).
Valuation over time computed as of each quarter's filing date
Revenue Breakdown
Annual revenue as the company disaggregates it in its own XBRL filings. Years a component wasn't reported show a dash.
Share mode is each component's slice of the reported components that year — issuers rarely tag every revenue dollar, so slices need not sum to total revenue.
By Segment (USD)
| Component | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Journey | $61,858,000 | $56,134,000 | $79,181,000 | — | — | — | — |
| Avenue Therapeutics Inc | $1,404,000 | — | — | — | — | — | — |
| Checkpoint | — | $41,000 | $103,000 | — | — | — | — |
| Dermatology Products Sales | — | — | $79,181,000 | $73,669,000 | $63,134,000 | $44,531,000 | $34,921,000 |
| Fortress Biotech Inc | — | $1,500,000 | $5,229,000 | — | — | — | — |
| Pharmaceutical and Biotechnology Product Development | — | — | $5,332,000 | $2,074,000 | $5,657,000 | $1,068,000 | $1,708,000 |
By Product & Service (USD)
| Component | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Qbrexza | $25,014,000 | $25,114,000 | $25,410,000 | $26,715,000 | $17,056,000 | $0 |
| Emrosi | $14,745,000 | $0 | — | — | — | — |
| Accutane | $12,882,000 | $19,407,000 | $20,168,000 | $18,373,000 | $10,053,000 | $0 |
| Foam Franchise Products | $5,859,000 | $6,652,000 | — | — | — | — |
| Other Legacy Product Revenue | $2,739,000 | $3,961,000 | $5,921,000 | — | — | — |
| Amzeeq | — | $5,009,000 | $6,201,000 | $7,242,000 | $0 | — |
| Collaboration Revenue | — | $1,500,000 | $5,229,000 | — | — | — |
| Exelderm | — | — | $2,395,000 | $3,463,000 | $5,363,000 | $4,453,000 |
| Luxamend | — | — | $35,000 | $0 | — | — |
| Other Branded Revenue | — | — | — | — | $37,000 | -$148,000 |
| Targadox | — | — | $3,204,000 | $7,972,000 | $22,378,000 | $30,708,000 |
| Ximino | — | — | $287,000 | $4,957,000 | $8,247,000 | $9,518,000 |
| Zilxi | — | $1,643,000 | $1,962,000 | $2,273,000 | $0 | — |
Segment Operating Income
Annual operating income by business segment, as tagged in the company's own XBRL filings. Segments need not sum to the consolidated figure — corporate costs and eliminations are typically unallocated.
By Segment (USD)
| Component | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| Mustang Therapeutics Inc | -$2,432,000 | -$16,245,000 | -$49,260,000 |
| Avenue Therapeutics Inc | -$3,083,000 | -$11,283,000 | -$14,540,000 |
| Journey | -$8,172,000 | -$13,677,000 | -$2,073,000 |
| Fortress Biotech Inc | -$18,496,000 | -$13,000,000 | -$24,321,000 |
| Checkpoint | -$38,038,000 | -$56,174,000 | -$52,148,000 |
Operating Margin by Segment (%)
| Component | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| Journey | -13.2% | -24.4% | -2.6% |
| Avenue Therapeutics Inc | -219.6% | — | — |
| Checkpoint | — | -137009.8% | -50629.1% |
| Fortress Biotech Inc | — | -866.7% | -465.1% |